Concentrations of medetomidine enantiomers and vatinoxan, an α2-adrenoceptor antagonist, in plasma and central nervous tissue after intravenous coadministration in dogs.

[1]  B. Pypendop,et al.  Effects of dexmedetomidine, with or without vatinoxan (MK-467), on minimum alveolar concentration of isoflurane in cats. , 2019, Veterinary anaesthesia and analgesia.

[2]  M. Scheinin,et al.  The impact of MK‐467 on plasma drug concentrations, sedation and cardiopulmonary changes in sheep treated with intramuscular medetomidine and atipamezole for reversal , 2018, Journal of veterinary pharmacology and therapeutics.

[3]  O. Vainio,et al.  Effects of MK-467 hydrochloride and hyoscine butylbromide on cardiorespiratory and gastrointestinal changes induced by detomidine hydrochloride in horses. , 2018, American journal of veterinary research.

[4]  B. Pypendop,et al.  Hemodynamic effects of dexmedetomidine, with and without MK-467, following intramuscular administration in cats anesthetized with isoflurane. , 2017, Veterinary anaesthesia and analgesia.

[5]  O. Vainio,et al.  Effects of constant rate infusions of dexmedetomidine or MK-467 on the minimum alveolar concentration of sevoflurane in dogs. , 2017, Veterinary anaesthesia and analgesia.

[6]  B. Pypendop,et al.  Pharmacokinetics of dexmedetomidine, MK-467 and their combination following intramuscular administration in male cats. , 2017, Veterinary anaesthesia and analgesia.

[7]  B. Pypendop,et al.  The impact of MK-467 on sedation, heart rate and arterial blood pressure after intramuscular coadministration with dexmedetomidine in conscious cats. , 2017, Veterinary anaesthesia and analgesia.

[8]  M. Scheinin,et al.  Plasma concentration and cardiovascular effects of intramuscular medetomidine combined with three doses of the peripheral alpha2-antagonist MK-467 in dogs. , 2017, Veterinary anaesthesia and analgesia.

[9]  B. Pypendop,et al.  The effect of MK-467, a peripheral α2-adrenoceptor antagonist, on dexmedetomidine-induced sedation and bradycardia after intravenous administration in conscious cats. , 2017, Veterinary anaesthesia and analgesia.

[10]  B. Pypendop,et al.  Cardiovascular effects of dexmedetomidine, with or without MK-467, following intravenous administration in cats. , 2017, Veterinary anaesthesia and analgesia.

[11]  M. Scheinin,et al.  Clinical effects and pharmacokinetic variables of romifidine and the peripheral α2 -adrenoceptor antagonist MK-467 in horses. , 2016, Veterinary anaesthesia and analgesia.

[12]  V. Rinne,et al.  Effects of MK-467 on the antinociceptive and sedative actions and pharmacokinetics of medetomidine in dogs. , 2016, Journal of veterinary pharmacology and therapeutics.

[13]  B. Pypendop,et al.  Pharmacokinetics of dexmedetomidine, MK-467, and their combination following intravenous administration in male cats. , 2016, Journal of veterinary pharmacology and therapeutics.

[14]  B. Pypendop,et al.  The effect of MK-467, a peripheral α2 -adrenoceptor antagonist, on dexmedetomidine-induced sedation and bradycardia after intravenous administration in conscious cats. , 2016, Veterinary anaesthesia and analgesia.

[15]  O. Vainio,et al.  Haemodynamic interactions of medetomidine and the peripheral alpha-2 antagonist MK-467 during step infusions in isoflurane-anaesthetised dogs. , 2014, Veterinary journal.

[16]  V. Rinne,et al.  Plasma drug concentrations and clinical effects of a peripheral alpha-2-adrenoceptor antagonist, MK-467, in horses sedated with detomidine. , 2013, Veterinary anaesthesia and analgesia.

[17]  W. McDonell,et al.  Cardiopulmonary and sedative effects of the peripheral α2-adrenoceptor antagonist MK 0467 administered intravenously or intramuscularly concurrently with medetomidine in dogs. , 2012, American journal of veterinary research.

[18]  V. Rinne,et al.  Influence of MK-467, a Peripherally Acting α2-Adrenoceptor Antagonist on the Disposition of Intravenous Dexmedetomidine in Dogs , 2012, Drug Metabolism and Disposition.

[19]  O. Vainio,et al.  The effects of increasing doses of MK-467, a peripheral alpha(2)-adrenergic receptor antagonist, on the cardiopulmonary effects of intravenous dexmedetomidine in conscious dogs. , 2011, Journal of veterinary pharmacology and therapeutics.

[20]  O. Vainio,et al.  The effects of L-659,066, a peripheral α2-adrenoceptor antagonist, and verapamil on the cardiovascular influences of dexmedetomidine in conscious sheep. , 2010, Journal of veterinary pharmacology and therapeutics.

[21]  O. Vainio,et al.  The effects of L-659,066, a peripheral α2-adrenoceptor antagonist, on dexmedetomidine-induced sedation and bradycardia in dogs. , 2008, Veterinary anaesthesia and analgesia.

[22]  F. J. Neto,et al.  Effects of a peripheral alpha2 adrenergic-receptor antagonist on the hemodynamic changes induced by medetomidine administration in conscious dogs. , 2008, American journal of veterinary research.

[23]  O. Vainio,et al.  The effects of L-659,066, a peripheral alpha2-adrenoceptor antagonist, on dexmedetomidine-induced sedation and bradycardia in dogs. , 2008, Veterinary anaesthesia and analgesia.

[24]  T. Mammoto,et al.  Supraspinal, Not Spinal, &agr;2 Adrenoceptors Are Involved in the Anesthetic-Sparing and Hemodynamic-Stabilizing Effects of Systemic Clonidine in Rats , 2000 .

[25]  C. Bryant,et al.  Characterisation of the cardiovascular pharmacology of medetomidine in the horse and sheep. , 1998, Research in veterinary science.

[26]  P. Pagel,et al.  A novel alpha 2-adrenoceptor antagonist attenuates the early, but preserves the late cardiovascular effects of intravenous dexmedetomidine in conscious dogs. , 1998, Journal of cardiothoracic and vascular anesthesia.

[27]  T. Guo,et al.  Dexmedetomidine Injection into the Locus Ceruleus Produces Antinociception , 1996, Anesthesiology.

[28]  M. Maze,et al.  Dexmedetomidine produces a hypnotic-anesthetic action in rats via activation of central alpha-2 adrenoceptors. , 1989, Anesthesiology.

[29]  J S Salonen,et al.  Pharmacokinetics of medetomidine. , 1989, Acta veterinaria Scandinavica. Supplementum.

[30]  Salonen Js,et al.  Pharmacokinetics of medetomidine. , 1989 .

[31]  V. J. Lotti,et al.  A peripherally acting alpha-2 adrenoceptor antagonist: L-659,066. , 1988, The Journal of pharmacology and experimental therapeutics.